CEL-SCI Corporation is a biotechnology company founded in 1983 that specializes in the research and development of immunotherapy products for the treatment of cancer, autoimmune diseases, and infectious diseases. Their core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. CEL-SCI's business strategy is centered around changing the way cancer is treated.

They aim to develop novel immune-based therapies that harness the body's own immune defense system to fight diseases, with minimal toxicity to normal cells and organ systems. Despite the challenges faced by small companies in the industry, CEL-SCI has shown significant long-term survival benefits for patients in a large Phase 3 head and neck cancer study. Their lead investigational therapy, Multikine®, is a potential therapeutic agent that enhances the body's anti-tumor immune response.

CEL-SCI's team is dedicated and passionate about boosting the patient's immune system to provide the greatest impact on cancer immunotherapy survival. Join CEL-SCI in their mission to change the world for the better with innovative immune-based therapies and make a real difference in the treatment of cancer and other diseases